MLNT - Melinta Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.7900
+0.2000 (+4.36%)
At close: 4:00PM EDT

4.7900 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close4.5900
Open4.6200
Bid4.7900 x 900
Ask4.8100 x 1100
Day's Range4.5400 - 4.8499
52 Week Range3.2000 - 46.0000
Volume207,336
Avg. Volume1,148,877
Market Cap53.791M
Beta (3Y Monthly)3.00
PE Ratio (TTM)N/A
EPS (TTM)-17.1200
Earnings DateMay 6, 2019 - May 10, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est51.00
Trade prices are not sourced from all markets
  • PR Newswire12 days ago

    Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    78 Presentations by Coalition Members During the Annual Meeting WASHINGTON , April 12, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant ...

  • GlobeNewswire16 days ago

    Melinta Therapeutics Announces Multiple Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that researchers are scheduled to present multiple scientific data presentations with data from its antibiotic portfolio at this year’s 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), April 13-16 in Amsterdam, Netherlands. “The body of data presented at ECCMID represents an important step in the global fight against antimicrobial resistance and delivering anti-infective solutions to patients,” said Sue Cammarata, M.D., chief medical officer of Melinta.

  • GuruFocus.comlast month

    Melinta Therapeutics Inc (MLNT) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Melinta Therapeutics Inc (NASDAQ:MLNT) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.

  • Melinta Therapeutics, Inc. (MLNT) Reports Q4 Loss, Tops Revenue Estimates
    Zackslast month

    Melinta Therapeutics, Inc. (MLNT) Reports Q4 Loss, Tops Revenue Estimates

    Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of -91.09% and 99.76%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswirelast month

    Melinta Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results

    ~ Reports Revenue of $96.4 million, Including Net Product Sales of $46.6 million, for the Full-Year 2018 ~ ~ Net Product Sales of $14.6 million for the Fourth Quarter of 2018,.

  • GlobeNewswire2 months ago

    Melinta Therapeutics to Report Fourth Quarter and Year-End 2018 Financial Results on March 13, 2019

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced it intends to release its fourth quarter and year-end 2018 financial results on March 13, 2019, after the close of the U.S. financial markets. Melinta will host a conference call and live webcast on Wednesday, March 13, 2019 at 4:30 p.m. ET to discuss its financial results and provide a business update. On March 13, 2019 at 4:30 p.m. ET, the live call may be accessed by dialing 877-377-7553 for domestic callers and 253-237-1151 for international callers and using conference ID #1698998.

  • TherapeuticsMD (TXMD) Catches Eye: Stock Jumps 6.1%
    Zacks2 months ago

    TherapeuticsMD (TXMD) Catches Eye: Stock Jumps 6.1%

    TherapeuticsMD (TXMD) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

  • GlobeNewswire2 months ago

    Melinta Therapeutics Announces Closing of Initial $75 Million Vatera Convertible Loan Funding

    MORRISTOWN, N.J., Feb. 25, 2019 (GLOBE NEWSWIRE) --  Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced the closing and receipt of the initial $75 million disbursement under the previously announced convertible loan facility from Vatera Healthcare Partners LLC on February 22, 2019. In addition, the previously announced amendment to the facility agreement with funds managed by Deerfield Management Company, L.P. (collectively, “Deerfield”) also became effective.

  • GlobeNewswire2 months ago

    Melinta Therapeutics Announces One-for-Five Reverse Stock Split

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that its Board of Directors has approved a one-for-five reverse stock split of the Company's common stock, par value $0.001. The reverse stock split, which was approved by the Company's stockholders at a special meeting held on February 19, 2019, will be effective at 5:00 pm Eastern Time today.

  • GlobeNewswire3 months ago

    Melinta Therapeutics Provides Corporate Updates

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today provided an update on its strategic repositioning initiatives, cost savings outlook, as well as new management appointments. The Company continues to execute on its strategic initiatives aimed at repositioning the business to drive profitable growth and value creation. “We have been moving with purpose and focus over the past several months to reposition Melinta and set a new trajectory towards growth and value creation,” said John H. Johnson, interim chief executive officer and director of Melinta Therapeutics.

  • PR Newswire3 months ago

    Antimicrobials Working Group Announces Updates to Leadership Team

    WASHINGTON , Jan. 17, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the appointment of a new Chairman, Evan Loh , M.D., President, Chief Operating Officer and Chief Medical ...

  • Adamis Pharmaceuticals (ADMP) Jumps: Stock Rises 5.3%
    Zacks4 months ago

    Adamis Pharmaceuticals (ADMP) Jumps: Stock Rises 5.3%

    Adamis Pharmaceuticals (ADMP) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

  • GlobeNewswire4 months ago

    John H. Johnson Agrees to Become Permanent Chief Executive Officer of Melinta Therapeutics

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that John H. Johnson has agreed to become the permanent chief executive officer (CEO) of Melinta, subject to the terms of an employment contract and the close of the previously announced commitment for a credit facility of up to $135 million from Vatera Healthcare Partners LLC. Mr. Johnson is a director of Melinta and has served as interim CEO of the Company since October 22, 2018. “John is a biopharmaceutical industry leader with a proven track record of growing businesses and unlocking value, and we are confident that he is the right person to lead Melinta into its next phase of growth and development,” said Kevin T. Ferro, chairman of Melinta Therapeutics.

  • GlobeNewswire4 months ago

    Melinta Therapeutics Announces Commitment for New Credit Facility of Up to $135 Million

    “We believe that, following negotiations and the expected close of a definitive agreement, this new credit facility from Vatera will take us to approaching cash flow breakeven as we continue to position Melinta to achieve profitable growth and drive stockholder value creation,” said John H. Johnson, interim chief executive officer and director of Melinta. “Since I became interim CEO, we have undertaken a number of operational improvements to lower costs and strengthen the business, and we are seeing the results of those efforts reflected in our accelerating sales momentum.

  • GlobeNewswire4 months ago

    Dova Pharmaceuticals Announces Management Changes

    Dr. David Zaccardelli appointed President and Chief Executive Officer Jason Hoitt appointed Chief Commercial Officer Company provides preliminary estimates of fourth quarter.

  • Zacks4 months ago

    Jazz (JAZZ) Increases Share Buyback Authorization by $400M

    Jazz's (JAZZ) board sanctions a raise in its share buyback authorization by $400 million.

  • GlobeNewswire5 months ago

    INVESTIGATION NOTICE:  Kaskela Law LLC Announces Investigation of Melinta Therapeutics, Inc. on Behalf of Stockholders – MLNT

    RADNOR, Pa., Nov. 30, 2018 -- Kaskela Law LLC is investigating Melinta Therapeutics, Inc. (“Melinta” or the “Company”) (NASDAQ: MLNT) on behalf of stockholders.  The.

  • GlobeNewswire5 months ago

    Melinta Therapeutics Granted European Commission Marketing Authorization for Vabomere® (meropenem and vaborbactam)

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that the European Commission (EC) has approved Vabomere® (meropenem and vaborbactam) for use in adult patients with complicated intra-abdominal (cIAI) and urinary tract infections (cUTI), hospital-acquired pneumonia including ventilator associated pneumonia (HAP/VAP), bacteraemia that occurs in association with any of these infections, and infections due to aerobic gram-negative organisms where treatment options are limited. Marketing authorization was granted in all 28 European Union (EU) member states, as well as Norway, Iceland and Liechtenstein.

  • GlobeNewswire5 months ago

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Board of Directors of Melinta Therapeutics, Inc.  

    NEW YORK, Nov. 26, 2018 -- Levi & Korsinsky announces it has commenced an investigation of Melinta Therapeutics, Inc. (NASDAQGS: MLNT) concerning possible breaches of.

  • ACCESSWIRE5 months ago

    STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Melinta Therapeutics, Inc. - MLNT

    RADNOR, PA / ACCESSWIRE / November 24, 2018 / Kaskela Law LLC is investigating Melinta Therapeutics, Inc. ("Melinta" or the "Company") (NASDAQ: MLNT) on behalf of the Company's stockholders. ...

  • GlobeNewswire5 months ago

    New Research: Key Drivers of Growth for Fresh Del Monte Produce, Liquidity Services, B.O.S. Better Online Solutions, ePlus inc, Pluralsight, and Melinta Therapeutics — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Nov. 16, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Associated Press6 months ago

    Melinta Therapeutics, Inc.: 3Q Earnings Snapshot

    The New Haven, Connecticut-based company said it had a loss of 50 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • Melinta Therapeutics, Inc. (MLNT) Reports Q3 Loss, Tops Revenue Estimates
    Zacks6 months ago

    Melinta Therapeutics, Inc. (MLNT) Reports Q3 Loss, Tops Revenue Estimates

    Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of 52.38% and 97.63%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire6 months ago

    Melinta Therapeutics Reports Third Quarter 2018 Financial Results

    New Product Launches Continue to Make Progress Setting the Stage for Growth in 2019Entered Commercial Agreement with Menarini Group to market Vabomere®, Orbactiv® and Minocin®.

  • GlobeNewswire6 months ago

    Melinta Therapeutics Announces Appointment of Bruce L. Downey to Board of Directors

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that the company has appointed Bruce L. Downey to its Board of Directors. Mr. Downey is an accomplished executive with over 35 years of corporate management, legal and development experience. Currently, Mr. Downey serves as a partner at NewSpring, a venture capital firm, and is a member of the board of directors of Cardinal Health, Inc., serving on the audit committee, and Momenta Pharmaceuticals, as well as privately held companies.